Presolin 150/Presolin 300

Presolin 150/Presolin 300 Warnings

irbesartan

Manufacturer:

Unison

Distributor:

Health Alliance
/
Firma Welfare Instrument
Full Prescribing Info
Warnings
May cause hyperkalemia. Avoid potassium supplementation unless specifically required by healthcare provider.
May be associated with deterioration of renal function and/or increase in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II.
Avoid use or use a much smaller dose in patients who are intravascularly volume-depleted.
Use with caution in patients with unstented unilateral or bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.
AUCs of irbesartan (not the active metabolite) are about 50% greater in patients with CrCl <30 mL/min and are doubled in hemodialysis patients.
Dual blockade of the renin-angiotensin-aldosterone system (RAAS): There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or Aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or Aliskiren is therefore not recommended. If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in